PortalPublikationenTransplantation of CD3/CD19 depleted allografts from haploid...

Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia

Standard

Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. / Lang, Peter; Teltschik, Heiko-Manuel; Feuchtinger, Tobias; Müller, Ingo; Pfeiffer, Matthias; Schumm, Michael; Ebinger, Martin; Schwarze, Carl P; Gruhn, Bernd; Schrauder, Andre; Albert, Michael H; Greil, Johann; Urban, Christian; Handgretinger, Rupert.

in: BRIT J HAEMATOL, Jahrgang 165, Nr. 5, 01.06.2014, S. 688-98.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lang, P, Teltschik, H-M, Feuchtinger, T, Müller, I, Pfeiffer, M, Schumm, M, Ebinger, M, Schwarze, CP, Gruhn, B, Schrauder, A, Albert, MH, Greil, J, Urban, C & Handgretinger, R 2014, 'Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia', BRIT J HAEMATOL, Jg. 165, Nr. 5, S. 688-98. https://doi.org/10.1111/bjh.12810

APA

Lang, P., Teltschik, H-M., Feuchtinger, T., Müller, I., Pfeiffer, M., Schumm, M., Ebinger, M., Schwarze, C. P., Gruhn, B., Schrauder, A., Albert, M. H., Greil, J., Urban, C., & Handgretinger, R. (2014). Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. BRIT J HAEMATOL, 165(5), 688-98. https://doi.org/10.1111/bjh.12810

Vancouver

Lang P, Teltschik H-M, Feuchtinger T, Müller I, Pfeiffer M, Schumm M et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. BRIT J HAEMATOL. 2014 Jun 1;165(5):688-98. https://doi.org/10.1111/bjh.12810

Bibtex

@article{1d694593fd704fb98789b6b4e430aeaa,
title = "Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia",
abstract = "Transplantation of T- and B-cell depleted allografts from haploidentical family donors was evaluated within a prospective phase II trial in children with acute lymphoblastic leukaemia, acute myeloid leukaemia and advanced myelodysplastic syndrome (n = 46). 20 patients had active disease; 19 patients received a second or third stem cell transplantation (SCT). Toxicity-reduced conditioning regimens consisted of fludarabine or clofarabine (in active disease only), thiotepa, melphalan and serotherapy. Graft manipulation was carried out with immunomagnetic microbeads. Primary engraftment occurred in 88%, with a median time to reach >1·0 × 10⁹/l leucocytes, >20 × 10⁹/l platelets and >0·1 × 10⁹/l T-cells of 10, 11 and 50 days, respectively. After retransplantation, engraftment occurred in 100%. Acute graft-versus-host disease (GvHD) grade II and III-IV occurred in 20% and 7%, chronic GvHD occurred in 21%. Both conditioning regimens had comparable toxicity. Transplant-related mortality (TRM) was 8% at one year and 20% at 5 years. Event-free survival at 3 years was: 25% (whole group), 46% (first, second or third complete remission [CR], first SCT) vs. 8% (active disease, first SCT) and 20% (second or third SCT, any disease status). This approach allows first or subsequent haploidentical SCTs to be performed with low TRM. Patients in CR may benefit from SCT, whereas the results in patients with active disease were poor.",
keywords = "Adolescent, Antigens, CD19, Antigens, CD3, Child, Child, Preschool, Feasibility Studies, Female, Graft Survival, Graft vs Host Disease, Haplotypes, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Immunocompromised Host, Infant, Leukemia, Leukemia, Myeloid, Acute, Lymphocyte Depletion, Male, Myelodysplastic Syndromes, Opportunistic Infections, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prospective Studies, Recurrence, Survival Analysis, Transplantation Conditioning, Treatment Outcome, Young Adult",
author = "Peter Lang and Heiko-Manuel Teltschik and Tobias Feuchtinger and Ingo M{\"u}ller and Matthias Pfeiffer and Michael Schumm and Martin Ebinger and Schwarze, {Carl P} and Bernd Gruhn and Andre Schrauder and Albert, {Michael H} and Johann Greil and Christian Urban and Rupert Handgretinger",
note = "keine UKE Affiliierung... kann nicht speichern GUW",
year = "2014",
month = jun,
day = "1",
doi = "10.1111/bjh.12810",
language = "English",
volume = "165",
pages = "688--98",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia

AU - Lang, Peter

AU - Teltschik, Heiko-Manuel

AU - Feuchtinger, Tobias

AU - Müller, Ingo

AU - Pfeiffer, Matthias

AU - Schumm, Michael

AU - Ebinger, Martin

AU - Schwarze, Carl P

AU - Gruhn, Bernd

AU - Schrauder, Andre

AU - Albert, Michael H

AU - Greil, Johann

AU - Urban, Christian

AU - Handgretinger, Rupert

N1 - keine UKE Affiliierung... kann nicht speichern GUW

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Transplantation of T- and B-cell depleted allografts from haploidentical family donors was evaluated within a prospective phase II trial in children with acute lymphoblastic leukaemia, acute myeloid leukaemia and advanced myelodysplastic syndrome (n = 46). 20 patients had active disease; 19 patients received a second or third stem cell transplantation (SCT). Toxicity-reduced conditioning regimens consisted of fludarabine or clofarabine (in active disease only), thiotepa, melphalan and serotherapy. Graft manipulation was carried out with immunomagnetic microbeads. Primary engraftment occurred in 88%, with a median time to reach >1·0 × 10⁹/l leucocytes, >20 × 10⁹/l platelets and >0·1 × 10⁹/l T-cells of 10, 11 and 50 days, respectively. After retransplantation, engraftment occurred in 100%. Acute graft-versus-host disease (GvHD) grade II and III-IV occurred in 20% and 7%, chronic GvHD occurred in 21%. Both conditioning regimens had comparable toxicity. Transplant-related mortality (TRM) was 8% at one year and 20% at 5 years. Event-free survival at 3 years was: 25% (whole group), 46% (first, second or third complete remission [CR], first SCT) vs. 8% (active disease, first SCT) and 20% (second or third SCT, any disease status). This approach allows first or subsequent haploidentical SCTs to be performed with low TRM. Patients in CR may benefit from SCT, whereas the results in patients with active disease were poor.

AB - Transplantation of T- and B-cell depleted allografts from haploidentical family donors was evaluated within a prospective phase II trial in children with acute lymphoblastic leukaemia, acute myeloid leukaemia and advanced myelodysplastic syndrome (n = 46). 20 patients had active disease; 19 patients received a second or third stem cell transplantation (SCT). Toxicity-reduced conditioning regimens consisted of fludarabine or clofarabine (in active disease only), thiotepa, melphalan and serotherapy. Graft manipulation was carried out with immunomagnetic microbeads. Primary engraftment occurred in 88%, with a median time to reach >1·0 × 10⁹/l leucocytes, >20 × 10⁹/l platelets and >0·1 × 10⁹/l T-cells of 10, 11 and 50 days, respectively. After retransplantation, engraftment occurred in 100%. Acute graft-versus-host disease (GvHD) grade II and III-IV occurred in 20% and 7%, chronic GvHD occurred in 21%. Both conditioning regimens had comparable toxicity. Transplant-related mortality (TRM) was 8% at one year and 20% at 5 years. Event-free survival at 3 years was: 25% (whole group), 46% (first, second or third complete remission [CR], first SCT) vs. 8% (active disease, first SCT) and 20% (second or third SCT, any disease status). This approach allows first or subsequent haploidentical SCTs to be performed with low TRM. Patients in CR may benefit from SCT, whereas the results in patients with active disease were poor.

KW - Adolescent

KW - Antigens, CD19

KW - Antigens, CD3

KW - Child

KW - Child, Preschool

KW - Feasibility Studies

KW - Female

KW - Graft Survival

KW - Graft vs Host Disease

KW - Haplotypes

KW - Hematopoietic Stem Cell Mobilization

KW - Hematopoietic Stem Cell Transplantation

KW - Histocompatibility Testing

KW - Humans

KW - Immunocompromised Host

KW - Infant

KW - Leukemia

KW - Leukemia, Myeloid, Acute

KW - Lymphocyte Depletion

KW - Male

KW - Myelodysplastic Syndromes

KW - Opportunistic Infections

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Prospective Studies

KW - Recurrence

KW - Survival Analysis

KW - Transplantation Conditioning

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1111/bjh.12810

DO - 10.1111/bjh.12810

M3 - SCORING: Journal article

C2 - 24588540

VL - 165

SP - 688

EP - 698

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 5

ER -